Next Article in Journal
Dietary Protein and Physical Activity Interventions to Support Muscle Maintenance in End-Stage Renal Disease Patients on Hemodialysis
Next Article in Special Issue
High Protein Diet and Metabolic Plasticity in Non-Alcoholic Fatty Liver Disease: Myths and Truths
Previous Article in Journal
Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese Subjects
Previous Article in Special Issue
Fermented Korean Red Ginseng Extract Enriched in Rd and Rg3 Protects against Non-Alcoholic Fatty Liver Disease through Regulation of mTORC1
Open AccessFeature PaperReview

Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered

1
Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università degli Studi di Genova, 16132 Genova, Italy
2
Programma Dipartimentale Diagnosi e Terapia delle Malattie Emergenti dell’Apparato Digerente, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
3
Divisione di Medicine Interna ed Epatologia, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy
4
Dipartimento di Scienze Biomediche, Humanitas University, 20090 Pieve Emanuele, Italy
5
Area Medicina Interna, Gastroenterologia e Medicina Interna, Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, 20123 Roma, Italy
6
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, no.6, 16132 Genoa, Italy
*
Author to whom correspondence should be addressed.
Maria Corina Plaz Torres and Alessio Aghemo share first authorship of the manuscript.
Luca Miele and Edoardo G. Giannini share last authorship of the manuscript.
Nutrients 2019, 11(12), 2971; https://doi.org/10.3390/nu11122971
Received: 11 November 2019 / Revised: 28 November 2019 / Accepted: 30 November 2019 / Published: 5 December 2019
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is expected to become the leading cause of end-stage liver disease worldwide over the next few decades. In fact, NAFLD encompasses different clinical scenarios, from the simple accumulation of fat (steatosis) to steatohepatitis (NASH), NASH-cirrhosis, and cirrhosis complications. In this context, it is fundamental to pursue strategies aimed at both preventing the disease and reducing the progression of liver fibrosis once liver damage is already initiated. As of today, no pharmacological treatment has been approved for NAFLD/NASH, and the only recommended treatment of proven efficacy are life-style modifications, including diet and physical exercise pointing at weight loss of 5%–7%. Different dietetic approaches have been proposed in this setting, and in this review, we will discuss the evidence regarding the efficacy of the Mediterranean Diet as a treatment for NAFLD. In particular, we will report the effects on liver-related outcomes. View Full-Text
Keywords: nonalcoholic steatohepatitis; chronic liver disease; lifestyle intervention; diet; outcome nonalcoholic steatohepatitis; chronic liver disease; lifestyle intervention; diet; outcome
Show Figures

Figure 1

MDPI and ACS Style

Plaz Torres, M.C.; Aghemo, A.; Lleo, A.; Bodini, G.; Furnari, M.; Marabotto, E.; Miele, L.; Giannini, E.G. Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Nutrients 2019, 11, 2971.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop